Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies has entered the elite league of Rs 1,000 crore plus market capitalization companies for the first time. Share price of the company hit a 52 week high of Rs 503.35 per share on August 24, 2023. Company aims to maintain healthy growth in revenue and margins in the coming years and has set a target of achieving Rs 750 crore revenue by FY26 while maintaining its 'Net Debt Free' status.
For FY23, the company has reported its Best-ever results in a financial year with highest - Revenue, EBITDA and Net Profit. Company achieved a milestone of Rs. 500 crore plus revenue and Rs. 100 crore plus profit before tax for the first time in a financial year. During Q1FY24 also, company reported an excellent operational and financial performance with Y-o-Y growth of 26.7% in Net Profit, 21.4% growth in EBITDA and 10.3% growth in Total Income.
Company has successfully completed expansion of the Cephalosporin plant at Mehsana, Gujarat. Commercial production from this plant has started and the company started selling in the domestic markets with product registration under process for many countries for exports.